- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Keytruda superior to chemotherapy in NSCLC study
17 June 2016 • Author: Victoria White, Digital Content Producer
The KEYNOTE-024 trial investigating the use of Merck’s Keytruda (pembrolizumab) in patients with previously untreated advanced non-small cell lung cancer (NSCLC) has met its primary endpoint.
KEYNOTE-024 is a Phase III study that compared the therapy to standard of care (SOC) platinum-based chemotherapies in the treatment of patients with advanced NSCLC whose tumours expressed high levels of PD-L1 (tumour proportion score of 50 percent or more). The study randomised 305 patients to receive Keytruda (200 mg every three weeks) or SOC platinum-based chemotherapies: paclitaxel+carboplatin, pemetrexed+carboplatin, pemetrexed+cisplatin, gemcitabine+carboplatin, or gemcitabine+cisplatin. Pemetrexed maintenance therapy was permitted for patients with non-squamous histologies. In addition, patients randomised to the control had the option of crossing over to pembrolizumab upon disease progression. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS) and overall response rate (ORR).
In this trial, the therapy was superior compared to chemotherapy for both the primary endpoint and the secondary endpoint of overall survival.
Commenting on the results, Dr. Roger M. Perlmutter, president, Merck Research Laboratories, said: “We believe that the KEYNOTE-024 results have the potential to change the therapeutic paradigm in first-line treatment of non-small-cell lung cancer. We look forward to sharing these data with the medical community and with regulatory authorities around the world.”
The safety profile of Keytruda in this trial was consistent with that observed in previously reported studies in patients with advanced NSCLC.
Merck currently has the largest immuno-oncology clinical development programme across the industry and is advancing five registration-enabling studies for NSCLC with Keytruda as a monotherapy and in combination.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics